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The assembly of HIV-1 virus particles is controlled by the 55 kDa
polyprotein precursor Gag (PrGag) protein, which is the key structural
protein of HIV-1 (Wills and Craven, 1991; Mervis et al., 1988;Wang et
al., 1998; Spearman et al., 1994; Reicin et al., 1996; Hermida-
Matsumoto and Resh, 1999; Freed, 1998; Ono et al., 2000; Huseby
et al., 2005). PrGag is composed of four major domains: matrix (MA),
capsid (CA), nucleocapsid (NC), and p6, as well as two small spacer
peptides, SP1 (between CA and NC) and SP2 (between NC and p6)
(Erickson-Viitanen et al., 1989; Kräusslich et al., 1995; Swanstrom and
Wills, 1997; Wiegers et al., 1998; Borsetti et al., 1998; Burniston et al.,
1999). MA is the component of PrGag that is responsible for its
binding to the plasma membrane (Zhou et al., 1994; Dalton et al.,
2007), which helps trigger immature virus particle release (Ono et al.,
2000; Li et al., 2007). During or just after immature particle release,
proteolytic processing of PrGag results in a conformational change
within CA that induces viral morphogenesis. As visualized by electron
microscopy (EM), electron dense conical or cylindrical cores com-
posed of about 1000–1500 CA proteins are evident in mature virus
particles (Briggs et al., 2003, 2006; Li et al., 2000). Also present within
mature cores are NC–viral RNA complexes, and experimental data
support a model in which NC binding to RNA helps nucleate coreassembly, perhaps by fostering CA dimerization (Dorfman et al., 1993;
Gorelick et al., 1993; Berkowitz et al., 1995; Zhang and Barklis, 1997;
Zhang et al., 1998; Dawson and Yu, 1998; Cimarelli et al., 2000;
Alfadhli et al., 2005; de Marco et al., 2010). Via microscopy analysis of
mammalian cells transfected with HIV constructs, it recently has been
validated that the viral RNA (vRNA) plays a scaffolding role in HIV-1
assembly, and that complexes of NC–vRNA located at cellular plasma
membranes are highly favored sites for assembly (Jouvenet et al.,
2009).
Mature HIV-1 CA possesses two independently folded domains; an
N-terminal domain (NTD) that is important for formation of CA
hexamers, and a C-terminal domain (CTD), that contributes to
hexamer formation and also fosters CA dimerization that is essential
for particle assembly (Gitti et al., 1996; Momany et al., 1996; Gamble
et al., 1997; Berthet-Colominas et al., 1999; Worthylake et al., 1999;
Ganser-Pornillos et al., 2007; Pornillos et al., 2009). The CA NTD is
composed of seven alpha helices, a cyclophilin (CypA) binding loop
between helices 4 and 5, and an N-terminal ß-hairpin loop composed
of the ﬁrst thirteen residues of CA. The interface formed by helices 1
and 2 makes NTD–NTD contacts that are essential for the assembly
and stabilization of CA hexamers both in vivo and in vitro, whereas
truncation of the CypA loop fosters the in vitro assembly of CA cores
(von Schwedler et al., 2003; Douglas et al., 2004; Ganser-Pornillos et
al., 2007; Barklis et al., 2009). Other studies have demonstrated that
the N-terminal ß-hairpin loop becomes stabilized after processing by
a salt bridge formed between residues 1 (proline) and 51 (aspartic
acid) and that the presence of the ß-hairpin correlates with mature
core assembly (Gamble et al., 1996; Gitti et al., 1996; Gross et al.,
138 C.S. López et al. / Virology 417 (2011) 137–1461998; von Schwedler et al., 1998; Tang et al., 2002; Abdurahman et al.,
2007; Monroe et al., 2010). The CA CTD is smaller than the NTD and is
composed of a short 310 helix followed by an extended strand and four
α-helices (Momany et al., 1996; Gamble et al., 1997; Berthet-
Colominas et al., 1999; Worthylake et al., 1999; Alcaraz et al., 2007;
Wong et al., 2008; Pornillos et al., 2009; Byeon et al., 2009). The CTD
appears to have the capacity to dimerize in several ways (Gamble et
al., 1997; Worthylake et al., 1999; Ternois et al., 2005; Ivanov et al.,
2007; Byeon et al., 2009), and the dimerization interface depends on
residues W184 and M185 (Gamble et al., 1997; Alcaraz et al., 2008;
Byeon et al., 2009; Yu et al., 2009). Recent evidence suggests that an
interface formed by the CTD dimers of three neighboring CA hexamers
might be involved in organizing intermolecular contacts of mature
HIV-1 cores (Byeon et al., 2009). In addition to the formation of dimer
and hexamer subunits, retroviral CA proteins have the capacity to
assemble pentamers, which allow capsid lattices to make closed core
structures similar to those of fullerene cones (Ganser et al., 1999 and
Li et al., 2000; Pornillos et al., 2011). Based on this type of structure,
HIV-1 cores are modeled to be composed of hexameric and
pentameric subunits, with seven pentamers located at one end of
the core, and ﬁve located at the narrow core end (Ganser et al., 1999;
Li et al., 2000; Pornillos et al., 2011).
A model for HIV-1 core assembly suggests that three steps may be
differentiated: a slow nucleation step, in which the nucleation species
is still unknown; a growth step that involves a fast polymerization of
the CA protein; and a termination step, which might involve the
capping of growing tubes (Barklis et al., 2009). Despite the current
structural information of CA hexameric and pentameric forms, it is
still not certain how andwhether dimers, hexamers and/or pentamers
contribute to the nucleation, growth or termination steps during core
assembly, and consequently the mechanisms by which HIV-1 CA
proteins assemble to form mature cores in vivo and in vitro are still
unknown. One puzzle is how postulated nucleation complexes might
serve as templates for rapid polymerization. Also unknown are the
factors that dictate sphere versus core or tube assembly, although
theoretical studies imply that the monomer orientations of CTDs and
NTDs may regulate the curvature of CA lattices (Nguyen et al., 2006;
Levandovsky and Zandi, 2009; Krishna et al., 2010).
Several reports have shown that CA cores assembled in vitro
resemble those observed in vivo (Li et al., 2000; Briggs et al., 2003;
Ganser-Pornillos et al., 2007; Byeon et al., 2009) affording investigators
an avenue to understanding the principles of mature core assembly. In
vitro assembly reactions using puriﬁed HIV-1 CA proteins result in the
formation of long tubes, although cones and spheres can be also
observed. In this study, we have examined factors that regulate CA
assembly using turbidity assays, ﬂuorescence microscopy (FM) and
electron microscopy (EM).We have focused our analysis on amino acid
residues located on CA NTD helices 1 and 6, and the ß-hairpin and
cyclophilin loops, to determinewhether perturbations of these residues
result in assembly defects that help elucidate the mechanisms of HIV-1
mature core assembly. Using this strategy, we have characterized CA
variants that show disparate assembly properties. Replacements of
amino acids located at the N- but not C-terminus of helix 1 (I15, R18),
and in the hairpin loop (Δ1–16, H12) impaired mature core assembly.
Interestingly, amino acid replacements of residues situated in the upper
face region of CA contained by NTD helix 6 (L111, W117), which is
adjacent to the ß-hairpin and Cyp-A loops, also impacted core
formation, indicating that NTD helix 6 is also a key element that
regulates CA assembly.
We further determined that one of our helix 1 mutant proteins was
capable of acting as a dominant negative with regard to CA tube
assembly, suggesting that the equilibrium between tube and sphere
formation can be easily skewed towards the termination of core
polymerization. Finally, EMexperiments using capsid plus nucleocapsid
(CANC)proteins andRNA to foster CAoligomerizationdemonstrate that
CA proteins appear to be triggered to switch conformations as theyoligomerize, and that assembled proteins facilitate the conversion of
new subunits to an assembly competent status. Mechanisms by which
nucleation scaffolds thus regulate HIV-1 core assembly are discussed.
Results
Effects of CA mutations on assembly
Tohelp elucidate themechanismofmatureHIV-1 core assembly, we
have analyzed factors that regulate the in vitro assembly of capsid tubes
from HIV-1 CA monomers. We examined the effects of mutations
targeted in CA NTD helices 1 and 6, and the β-hairpin and cyclophilin
loops. The CA residues on helix 1 targeted for amutational analysiswere
isoleucine 15 (I15), proline 17 (P17), arginine 18 (R18), asparagine 21
(N21) and lysine 25 (K25) (Figs. 1A and B). I15 was mutated based on
the notion that this residuemight be involved in the correct positioning
of the β-hairpin loop that is formed during HIV-1 core maturation
(Fig. 1B), whereas residues R18, N21 and K25 possess side chains that
point toward neighbor CA proteins within hexamers, potentially
organizing CA hexameric lattices (Fig. 1A). We examined a ß-hairpin
loop deletion protein (Δ1–16; Fig. 1) to extend previous observations
(Gross et al., 1998),whichsuggested thatdeletionof theﬁrst 13 residues
of CA was compatible with assembly. We also tested the effects of
mutating one residue locatedwithin the hairpin loop (H12; Figs. 1C and
D), one residue in the CypA loop (M96; Figs. 1C and D), and a deletion of
the CypA loop itself. To complement these studies, other residues
located in the upper face loop region of CA NTD were targeted. In
particular, mutations at helix 6 residues L111 and W117 were
generated. These were of interest because helix 6 is adjacent to the
biologically important ß-hairpin and CypA loops, and the inﬂuence of
helix 6 on assembly has as yet not been investigated in detail.
To monitor how mutations affected the kinetics of CA assembly we
measured oligomerization of puriﬁed WT and mutant CA proteins
spectrophotometrically (Lanman et al., 2002; Tang et al., 2003; Douglas
et al., 2004; Sticht et al., 2005; del Alamo et al., 2005; Abdurahman et al.,
2007; Barklis et al., 2009). The time-dependent formation of light-
scattering CA assembly products was monitored for 60 min, and
examples of turbidity assay plots are provided in Figs. 2A and B. In
Figs. 2C and D maximum absorbance readings from multiple experi-
ments are graphed for all the mutant proteins. As illustrated in Fig. 2A,
theP17AmutantCA, aswell as the conservativeK25Rmutant assembled
efﬁciently, whereas the mutant proteins I15D, R18L and, N21L
assembled considerably less well than the WT counterpart. As shown
in Fig. 2B, one of the helix 6 mutants, L111W, showed higher turbidity
values than WT, while the Δ87–97, H12A, and M96A mutants gave
roughly WT results. Relative to WT, several helix 1 mutant proteins
(I15D, R18H, R18L, R18E, N21L; Figs. 2A and C) gave low turbidity
values, indicative of the importance of helix 1 inmakingprotein contacts
critical tomature core assembly.We also observed reduced signals from
the Δ1–16 ß-hairpin mutant (Figs. 2B and D), consistent with
assignment of the ß-hairpin as a regulator of core morphology.
Additionally, several helix 6 variants (L111A, L111F, W117A; Figs. 2B
and D) demonstrated low to minimal turbidity signals. This was
unexpected, because helix 6 previously has not been earmarked as a
determinant of core assembly.
Because turbidity assays cannot distinguish between properly
assembled tubes and non-speciﬁc protein aggregation, we also
monitored CA assembly by ﬂuorescence microscopy (FM), using a
method that we recently developed for this purpose (Barklis et al.,
2009). Brieﬂy, assembly products are adhered to glass coverslips and
detected by immunoﬂuorescence such that tubes appear as bright
lines against a black background. As an example, in Figs. 3A–D, FM
images of the WT, I15D, Δ1–16 and L111W assembly products are
shown. Assembled CA tubes were evident as ﬂuorescent (white) lines,
particularly with the WT (Fig. 3A) and L111W (Fig. 3D) samples. Such
products were rarely seen in the I15D and Δ1–16 proteins (Figs. 3B
Fig. 1. Locations of HIV-1 CA mutations. The locations of HIV-1 CA helix 1 mutations red (I15), orange (P17), magenta (R18), black (N21) and turquoise (K25) are viewed down the
sixfold axis of the CA hexamer (A) and on a monomer model, perpendicularly oriented relative to the hexamer view (B). The locations of HIV-1 CA helix 6 mutations H12 (red), M96
(orange), L111 (magenta), andW117 (black) are viewed down the sixfold axis of the CA hexamer (C) and on a monomer model oriented as in B (D). CA NTDs are colored blue; CTDs
are colored green; β-hairpins are colored light blue; and the NTD h1 and h6 helices are colored in yellow. The atomic map derives from PDB 3GV2.
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assembly products, were observed. To quantitate results for all the
mutants, areas covered by tubes were determined and normalized to
WT tube coverage values (Figs. 3E and F). As illustrated, except for
Δ87–97 (Fig. 3F), all other variants gave reduced numbers of CA tubes.
However, several lysine 25mutant proteins (K25A, K25R, K25E, K25L)
gave at least 25% as many tubes as WT CA (Fig. 3E), as did one
conservative helix 6 mutant (L111W), and mutations at M96 in the
cyclophilin loop (Fig. 3F). These results are in agreement with
turbidity assay results (Fig. 2), and support the notion that alterations
in the CypA loop and the C-terminal portion of helix 1 are tolerated for
assembly. In contrast, the lowest levels of tube assembly products
observed by FM were for N-terminal helix 1 mutant proteins (I15,
R18; Fig. 3E), ß-hairpin variants (Δ1–16, H12A; Fig. 3F), and several
helix 6 mutant proteins (L111A, L111F, W117A; Fig. 3F). With some
exceptions, notably H12A, these results generally correlate with
turbidity results, and emphasize the roles of the ß-hairpin and the
N-terminus of helix 1 in mature core assembly. They also identify
helix 6 as a novel participant in the process.
To complement FM analyses, low magniﬁcation EM images of
assembly products also were collected. In Figs. 4A–D, examples are
illustrated of WT tubes, of short tubes assembled by L111W and of
aggregates and spheres formed by I15D andΔ1–16 proteins. Aswith FMobservations, EM results for all proteins were quantiﬁed in terms of
relative tube assembly efﬁciencies (normalizedpercentage area covered
by tubes; Figs. 4E and F). Consistentwith FManalysis (Fig. 3),mutations
thatmost dramatically reduced tube assembly located to theN-terminal
part of helix 1 (I15, R18; Fig. 4E), the ß-hairpin (Δ1–16, H12; Fig. 4E),
and helix 6 (L111, W117; Fig. 4F). Thus, in addition to structural
elements known to impact mature core formation (ß-hairpin, helix 1),
helix 6 also contributes to assembly.
Analysis of assembly inhibition and initiation
As illustrated in Figs. 2–4 above, the I15D replacement in CA NTD
helix 1 resulted in the inability of this CA variant protein to adopt an
assembly proﬁcient conformation. Indeed, the protein consistently
scoredamong themost assembly-impairedprotein variants. Toevaluate
its effect on assembly competent proteins, we decided to perform
coincubations of I15D and the assembly proﬁcient protein Δ87–97,
which assembled long tubes as viewed by FM (Figs. 5A–C). For our
purposes, the Δ87–97 and I15D proteins were mixed in micromolar
ratios of 200/0, 150/0, 100/0, 150/50, 100/100 and 50/150 and allowed
to assemble. Incubation products then were subjected to FM analysis
(Fig. 5). In the absence of I15D proteins, theΔ87–97 proteins assembled
efﬁciently into tubes at 200, 150 and 100 μMconcentrations. In contrast,
Fig. 2. Effects of mutations on in vitro assembly reactions. In vitro assembly reactions were performed as described in theMaterials andmethods section, and assembly wasmonitored
by plotting 350 nm optical density (OD) absorbance values (normalized to those ofWT) versus time. In (A), the plots are ofWT (black circles), I15D (inverted triangles), P17A (black
diamonds), R18L (open circles), N21L (open squares), K25L (triangles), and K25R (black squares). In (B), the plots are of WT (black circles), Δ1–16 (inverted triangles), H12A (open
squares), Δ87–97 (black squares) M96A (open circles), L111W (triangles), and W117A (black diamonds). In (C) and (D), the maximum 350 nm OD readings obtained after 60 min
incubations for all variants are shown, along with standard deviations. All panels derive from a minimum of at least three independent experiments and show standard deviations,
but with some timepoints in panels A–D, the standard deviations are too small to be resolved on the plot.
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the numbers of observed tubes (Figs. 5D–F). Normalized tube coverage
values are depicted in Fig. 5G. These data showed that as little as one
quarter I15D in an assembly reaction of 200 μM total protein poisoned
CA tube assembly. Since 100 μM Δ87–97 by itself assembled tubes
efﬁciently (Figs. 5C and F), the ability of 50 μMI15DCA to inhibit 150 μM
Δ87–97 CA from tube formation suggests that one defective CA
monomer can impair the activity ofmore than one assembly competent
partner. In an effort to analyze if the I15D and Δ87–97 proteins were
homogeneously combinedwithin tubes in theﬁnal assembled products,
or if there might be a preferential localization of different proteins, we
separately tagged the I15D and Δ87–97 proteins with myc and ﬂag
epitope tags at their C-termini. Assembly products then were subjected
to FM using ﬂuorescently labeled primary antibodies against the myc
andﬂag tags as indicated in theMaterials andmethods. Interestingly,we
observed that the few tubes present in mixed incubations showed an
apparent homogeneous distribution of both proteins, suggesting that
I15D mutant protein incorporation into tubes did not invariably block
tube growth (data not shown).
As a complementary approach to the analysis of CA tube assembly,
we have examined the mechanism of tube assembly nucleation. To do
so, we took advantage of the fact that HIV-1 CANC proteins can be
promoted to assemble tubes under low salt conditions via the
addition of RNA. Thus, it is possible to examine how CANC assembly
might affect the assembly of CA proteins under conditions inwhich CA
proteins alone don't ordinarily assemble. For the purpose of this study,
because CANC plus RNA assembly incubations generated short tubes
in our hands, assembly was monitored via EM. As controls, CANC
proteins by themselves were incubated in low salt conditions, in the
presence of RNA at two different conditions. With these controls, large
numbers of tubes were seen at high (30 μM) CANC concentrations
(Fig. 6A) while only a few small tubes were observed at low CANC
(3 μM) concentrations (Fig. 6B). We then asked whether incubations
of RNA plus low concentrations of CANC might be able to nucleate the
tube formation of CA proteins under conditions where CA proteinsdon't normally assemble. To test this, RNA and 3 μM CANC were
preincubated 30 min under low salt conditions, and then Δ87–97 CA
(40 μM) proteins were added, after which samples were incubated an
additional 24 h. Importantly, to avoid CA self-assembly in these
samples, the ﬁnal NaCl concentrations never exceed 25 mM. An
example of the products of such an incubation is provided in Fig. 6C.
As illustrated, an abundance of small tubes was evident. However, if
any of the three incubation components, CA, CANC, or RNA were
removed, tube assembly was abolished (Fig. 6D). Thus, the presence
of CANC and RNA in low salt conditions triggers HIV-1 CA tube
assembly.
We extended these investigations in experiments where CANC
proteins in tubes assembled as described above were localized within
tubes via immunogold labeling. For these studies, WT CANC proteins
and assembly-competent Δ87–97 CA proteins were employed so that
the locations in tubes of CANC proteins could be tracked with a primary
antibody directed against the CypA loop. As shown in Figs. 7A and B, in
incubations where Δ87–97 CA proteins were assembled themselves
under high salt conditions, very few gold particles (indicated by black
dots) were observed, demonstrating that the Δ87–97 proteins do not
bind well to the CypA loop-directed antibody. In contrast, tubes
assembled from RNA and high concentrations of WT CANC proteins
(Figs. 7C and D) were decorated with gold particles. Tubes assembled
under low salt conditions with RNA, low concentrations of WT CANC
and high concentrations of Δ87–97 CA also bound gold particles (Figs.
7E–G). It is noteworthy that for incubations containing WT CANC
proteins, not all gold particles were tube associated, but this is to be
expected, as unassembled and partially assembled CANC proteins will
adhere to EM grids and subsequently bind the primary anti-CypA loop
antibody and secondary gold-conjugated antibody. For quantitative
purposes, to estimate the speciﬁcity of antibody binding, we calculated
the numbers of gold particles along tube lengths and obtained the
following values for the three different incubations: Δ87–97 CA
incubations alone, 2.3 particles/micrometer (N=69 tubes); RNA plus
WT CANC, 97.0 particles/micrometer (N=34); RNA plusWT CANC plus
Fig. 3. FM analysis of CA NTDmutant assembly products. WT and CA variant proteins at
80 μMwere induced to assemble at 4 °C for 48 h and then processed for visualization by
FM. Examples of assembly results for WT (A), I15D (B), Δ1–16 (C), and L111W (D) are
shown, where tubes appear as white lines; aggregates and spheres appear as white
dots; and the size bar for A–D is as shown in panel D. In panels E and F, tube coverage
was calculated from at least ﬁve 14,370 μm2 ﬁelds of view of two independent samples
for all the CA variants. Results are given as areas covered by tubes, after normalization of
results obtained with WT CA.
Fig. 4. EM analysis of CA NTDmutant assembly products. WT and CA variant proteins at
80 μMwere induced to assemble at 4 °C for 48 h and then processed for viewing by EM
after negative staining with uranyl acetate. Examples of assembly results for WT
(A), I15D (B), Δ1–16 (C), and L111W (D) are shown, where tubes appear as gray rods;
aggregates and spheres appear as black dots or clusters of dots; and the size bar for A–D
is as shown in panel D. In panels E and F, tube coverage was calculated from at least six
17.1 μm2 ﬁelds for all CA variants. Results are given as percentage of areas covered by
tubes, after normalization of results obtained with WT CA.
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that the anti-CypA loop antibody indeed is speciﬁc for CANC proteins in
these incubations.
Given the speciﬁcity of WT CANC protein detection, we next
localized CANC proteins in RNA plus CANC tubes (Figs. 7C and D) and
in RNA plus CANC plus Δ87–97 CA tubes (Figs. 7E–G). By visual
inspection, it appeared that particles on RNA plus CANC tubes were
distributed evenly along the lengths of the tubes. In contrast, RNA plus
CANC plus Δ87–97 CA tubes showed asymmetric concentrations of
particles, usually localized to the end of one tube (Figs. 7E and F, to the
left of the arrowheads), but occasionally (two tubes), localized towards
the center of the tube (Fig. 7G, between arrowheads). We interpret
these images to indicate that short tubes formed from RNA plus CANC
proteins can nucleate the assembly of CA proteins either unidirection-
ally (Figs. 7E and F), or occasionally bidirectionally (Fig. 7G). To
quantitate our results, particles were counted along the lengths of
multiple tubes from the tube ends thathad thehighest concentrationsof
gold particles (deﬁned as the zero ends). In Fig. 7H, the counts are
depicted as total particle counts within segments at various distances
away from tube zero ends. As shown (Fig. 7H, white bars), tubescomposed purely of RNA and CANC proteins demonstrated roughly
equal particle counts along their lengths. In contrast, tubes assembled
under low salt conditions from RNA,WT CANC andΔ87–97 CA proteins
were highly decorated at their zero ends and substantially less
decorated at their opposite ends (Fig. 7H, black bars). These results
show that CANC proteins localize to single ends of these tubes, and
imply that RNA plus CANC assemblies nucleated the assembly of CA
proteins. Our results are discussed in further detail below.
Discussion
In this work we have analyzed themechanism of mature HIV-1 core
assembly and the contributions of structural elements to the assembly
process. For structural analysis, amino acid modiﬁcations of helices 1
and 6, and β-hairpin, and CypA loops residues were evaluated for their
effects on mature core assembly. Our results indicate that amino acid
changes in helix 1 residues P17 and K25 did not impair assembly
(Figs. 2–4). These results were somewhat unexpected because the two
residues are highly conserved among HIV CA proteins, and also are
located at the helix 1NTD intra-hexamer interface. In contrast, the other
mutations analyzed onhelix 1 (I15, R18, N21) and those at theß-hairpin
loop (Δ1–16, H12) showed altered assembly properties (Figs. 2–4).
Fig. 5. Effects of I15D proteins on CA assembly.Δ87–97 and I15D proteins at the indicated
Δ87–97/I15D concentration ratios were mixed and induced to assemble at 4 °C for 48 h
and then processed for visualization by FM. Examples of assembly results for the indicated
protein ratios are shown in panels A–F, with the size bar for all these panels in panel F. In
panel G, tube coverage was calculated from at least ﬁve 14,370 μm2 ﬁelds of view of two
independent samples for the indicated mix ratios. Results are given as area covered by
tubes, after normalization of results obtained with the 200 μM Δ87–97/0 μM I15D mix.
Fig. 6. Assembly of CA and CANC proteins. Panels A–C show EM images of products
assembled from RNA (30 μM total nt concentration) and either 30 μM CANC (A), 3 μM
CANC (B), or 3 μM CANC plus 40 μM CA protein (C). In panel D, tube coverage was
calculated fromat least six 17.1 μm2ﬁelds fromsamples composedofRNA, 3 μMCANCand
40 μM CA (RNA+CANC+CA); RNA plus 3 μM CANC (−CA); RNA plus 40 μM CA
(−CANC); or 3 μM CANC plus 40 μM CA (−RNA). Results are given as percentage of tube
area covered by tubes, after normalization of results obtained for the RNA+CANC+CA
mix. Note that the average value of theRNA+3 μMCANC+40 μMCAmix (corresponding
to panel C) was 59% that obtained with the RNA+30 μM CANC (panel A) incubation.
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short tubes, we infer that these proteins are able to nucleate assembly,
but that termination occurs prematurely. While previous work
suggested that the R18 and N21 residues impact CA assembly, the
abnormal assembly observed for the I15 variant may indicate that the
side chain of this residue stabilizes or directs the positioning of the
β-hairpin loop. Moreover, in contrast to previous results that showed a
Δ1–13 deletion of ß-hairpin was compatible with tube assembly (Gross
et al., 1998), our data suggest that a deletion of sixteen residues (Δ1–16)
impairs mature-type tube formation. One caveat to making distinctions
between the assembly properties of the Δ1–13 and Δ1–16 proteins is
that the proteinswere examined indifferent studies.However, since the
Δ1–16 deletion includes the I15 residuementioned above, onemodel of
ß-hairpin's role is that it functions to align residues I15 and D51 located
in NTD helices 1 and 3 to formNTD–NTD interfaces that are essential for
core assembly. Since both the ß-hairpin and CypA loops project away
from the centers of cores on CA NTDs, we also were interested in
whether mutations at NTD helix 6, situated between these two loops,
might affect assembly. Interestingly, we have determined that amino
acid replacements of residues L111 and W117 greatly impaired core
assembly (Figs. 3 and 4). These data indicate a novel contribution of
helix 6 in the control of HIV-1 core morphogenesis and it will be of
interest to determine how this regulation occurs.
In addition to evaluating the assembly properties of CA variants, we
also have examined how core assembly is terminated and nucleated. As
noted above, the I15Dprotein appears to terminate the growth of capsid
tubes. Moreover, when mixed with assembly-competent Δ87–97
proteins very few tubes were observed (Fig. 5) suggesting that onedefective CA monomer can impair the activity of more than one
assembly competent partner. We envision that I15D proteins may
inhibit Δ87–97 tube formation by promoting the capping of tubes
resulting in the termination of the polymerization process.
In a second set of mixing experiments, we examined whether
short pre-assembled complexes composed of CANC and RNA were
able to promote the growth of CA tubes (Fig. 6). Our results indicate
that CANC–RNA nucleation complexes acted as seeds for CA tube
assembly. To extend this study, we performed immunogold labeling
experiments to localize CANC proteins in assembled tubes (Fig. 7).
Using this technique, we determined that tubes assembled from RNA,
WT CANC, and CA proteins have a preferential distribution of the
CANC proteins toward one end, implying that CANC–RNA nucleation
complexes indeed nucleated the assembly of CA proteins. Our
observations favor a two-step assembly mechanism in which viral
RNA plays a nucleating role in HIV-1mature core assembly. In the ﬁrst
step, nucleation complexes are formed from CANC and RNA; and in a
second step, free CA proteins are recruited via speciﬁc CA–CA
interactions. Our evidence suggests that CA proteins convert to
assembly-proﬁcient conformations as they become associated with
growing cores. In this regard, it is expected that these CA
conformations may be similar to those adopted by CA proteins
under assembly-inducing high salt conditions. We also determined
that in rare cases (two), nucleation complexes were able to initiate
the bidirectional growth of CA tubes (Fig. 7G), indicating that
nucleation mostly generated complexes that become capped on one
end. We believe that further dissection of these assembly steps will
foster the development of antivirals capable of blocking HIV-1 core
assembly.
Materials and methods
Recombinant DNA constructs
The parental construct for these studies is pWISP-WTCAH6 (Barklis
et al., 2009), which derives from pWISP-98-85 (Li et al., 2000; Ganser-
Pornillos et al., 2004), which was kindly provided by Wes Sundquist.
Fig. 7. Immunogold incubations of CA and CANC proteins. Panels A–G show EM images of products assembled from RNA (30 μM total nt concentration) and either 40 μM of Δ87–97
CA proteins (A and B), 30 μM CANC (C and D), or 3 μM CANC plus 40 μM Δ87–97 CA protein (E–G). The primary antibody used for this assay is speciﬁc for the CA cyclophilin loop
present only in the CANC proteins, and the secondary antibody was gold-conjugated. Gold particles along the tubes can be observed as large black dots. Note that the total numbers of
gold particles along tube lengths for the incubations were as follows: Δ87–97 CA alone, 2.3 particles/micrometer (N=69 tubes); RNA plus WT CANC, 97.0 particles/micrometer
(N=34); RNA plusWT CANC plusΔ87–97 CA, 45.0 particles/micrometer (N=57). In panel H, particle counts were calculated along tube lengths from 57 assembled tubes composed
of RNA plus 3 μM CANC plus 40 μM Δ87–97 CA proteins (black histogram) or 34 tubes of RNA plus 30 μM CANC (white histogram). Note that tube zero ends are deﬁned as the tube
ends that had the highest concentrations of gold particles.
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proteins; and his-tags, which do not interfere with assembly reactions
(Barklis et al., 2009), were not cleaved from the proteins. Mutations
were created by standard molecular biology techniques and were
sequenced. Mutations are named by the convention where the WT
HIV-1 CA residue is listed, followed by the new residue at the mutated
position. Nucleotide sequences for point mutations are given below,
where underlined nucleotides correspond to the mutated residue, and
bold nucleotides represent silent mutations that create or destroy
restriction enzyme cleavage sites: H12A, ATG GTTGCG CAG GCG; I15D,
CAG GCC GAC TCA CCG CGG; I15A, CAG GCC GCTAGC CCT; P17A, GCG
ATAAGTGCACGAACT; R18L, GCGATATCACCTCTGACT TTA; R18E, ATA
TCT CCGGAA ACG TTA; R18H, GCG ATA TCA CCT CAC ACG TTA; R18C,
GCG ATA TCT CCG TGC ACG TTA; N21L, GCG ATA TCA CCT CGT ACG TTA
CTT GCA TGG; K25A, GCA TGG GTTGCG GTA GTA GAA GAA GCT; K25E,
GCA TGG GTA GAG GTA GTA GAA GAA; K25R, GCA TGG GTA CGC GTA
GTA GAAGAA; K25L, GCA TGG GTA CTG GTA GTA GAA GAA; K25C, GCA
TGG GTA TGC GTA GTA GAA GAA; M96A, CCC GGG CAG GCTCGA GAA;
M96W, CCC GGC CAG TGG AGA GAA; L111A, ACT AGT ACC GCC CAG
GAA; L111F, ACTAGTACCTTCCAGGAA; L111W,ACTAGTACCTGGCAG
GAA; W117A, ATA GGC GCC ATG ACA. For deletion mutations, the
cyclophilin loop deletion (Δ87–97) corresponds to pWISPΔCycloop-
CAH6 (Ganser-Pornillos et al., 2004), while the β-hairpin deletion
(Δ1–16) was constructed by eliminating CA codons 1–16. In this case,
the nucleotides encoding the CA primary translation product are ATG
CCGCGG ACC TTA AAT GCA, where bold nucleotides indicate silent
changes to alter restriction sites, the underlined triplet corresponds to
codon 17 (proline) and the preceding ATG is the initiator methionine.
Previously it has been shown that the initiator methionine of the WT
HIV-1 CA protein, which also precedes a proline residue, is removed
efﬁciently in E. coli (Li et al., 2000; Ganser-Pornillos et al., 2004), but we
have not veriﬁed that this is the case with our Δ1–16 construct. In
certain experiments, we also have used CA proteins that have been Flag(DYKDDDDK) or Myc (EQKLISEEDL) tagged at their C-termini. The
nucleotide sequences at the C-termini of these variants are as follows,
where the starting TTG represents the ﬁnal CA codon, a created NotI
restriction site is italicized, the Flag or Myc tag codons are underlined,
and the polypeptide nonsense codon is in bold: Flag, TTG CAT CAT CAT
CAT CAT CAT GCG GCC GCG GAT TAT AAG GAC GAC GAC GAC AAGTAG;
Myc, TTG CAT CAT CAT CAT CAT CAT GCG GCC GCG GAG CAG AAG CTT
ATC TCGGAGGAAGAT CTCTAG. We also employedWTorΔ87–97HIV-
1 CANC expression constructs that retain the CA coding regions of their
namesakes, but express natural HIV-1 CANC proteins with no his tags.
These constructs were kindly supplied by Barbie Ganser-Pornillos.
Protein puriﬁcation
Plasmids were transformed into the E. coli strain BL21(DE3)/pLysS
(#69451; Novagen) for protein expression and puriﬁcation, which
followed previous procedures (Barklis et al., 2009). Brieﬂy, bacteria
were grown in Luria–Bertani (LB) broth supplemented with 0.02%
maltose and 10 mMMgSO4 to a 600 nm optical density (OD) of about
0.4, and then induced at 25 °C for 3 h via the addition of 0.5 mM
isopropyl-β-D-thiogalactopyranoside (IPTG; Roche #11411446001).
In some cases lactose at 1% (w/v) was added instead of IPTG for
protein induction. Induced bacteria were collected by centrifugation
(Sorvall GSA 5000 rpm, 3000×g, 4 °C) and frozen at −80 °C.
For CA proteins, bacterial pellets were suspended in 10 ml of ice cold
50 mM NaH2PO4 pH 7.8, 300 mM NaCl containing 0.5 mg of DNaseI
(Roche #10104159001) plus protease inhibitors (15 μg/ml leupeptin,
36 μg/ml egg-white trypsin inhibitor, 36 μg/ml soybean trypsin inhib-
itor, 30 μg/ml aprotinin, and 1.5 mM phenylmethylsulfonyl ﬂuoride;
Sigma). After a 10 min incubation on ice, bacterial suspensions were
French-pressed twice, cleared by centrifugation at 23,000×g (Sorvall
SS34, 14,000 rpm) for 15 min at 4 °C, and puriﬁed by one to two rounds
of nickel chelate chromatography (Qiagen Ni-NTA resin, #30210). Non-
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concentration (10 mM, 25 mM and 50 mM) in wash buffer (50 mM
NaH2PO4 pH 6, 300 mM NaCl, 10% glycerol), and CA proteins were
subsequently eluted in 250 mM imidazole. Puriﬁed fractions were
subjected to three rounds of buffer exchange bydialysis in buffer 20 mM
Tris pH 8.0, 5 mMβ-mercaptoethanol (β-Me) for 6 h at 8 °C and protein
aliquots were ﬂash frozen on dry ice and stored at −80 °C. Protein
identities were assessed by immunoblotting (Barklis et al., 2009), and
protein purities of N90% were veriﬁed by Coomassie blue staining of
samples fractionated by sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE). Previous investigations suggest that the
low (b10%) levels of E. coli protein contaminants in CA preparations do
not interfere with capsid assembly reactions (Ganser-Pornillos et al.,
2004; Barklis et al., 2009), but it is possible that minor assembly
differences between proteins may be due to minor purity differences.
Protein concentrations were determined via 280 nm absorbance
readings assuming a molar extinction coefﬁcient of 33,580, and by
densitometric comparison of stained SDS-PAGE protein bands versus
known standards.
For the puriﬁcation of CANC proteins, French pressed lysates,
prepared as described above, were treated to remove nucleic acids via
the addition of 1/167 parts (v/v) of 50% polyethylenimine (Sigma
P3134; 0.3% ﬁnal concentration). Mixtures were incubated on ice for
10 min, and nucleic acid precipitates were removed by 15min, 4 °C
centrifugation at 23,000×g. CANC proteins were precipitated from
supernatants by the addition of 0.176 g (NH4)2SO4 perml of lysate (30%
ﬁnal concentration), stirring, incubation on wet ice for at least 1 h, and
centrifugation as above. Precipitates were suspended in cold loading
buffer (25 mM NaH2PO4, 150 mM NaCl, pH 7.8) and puriﬁed by two
rounds of IMAC-Zn (IMAC Sepharose 6 Fast Flow; GE Healthcare
17-0921-67) afﬁnity resin using standardmethods (Ganser et al., 1999).
Brieﬂy, 1 ml columns were loaded with 200 mM zinc chloride (pH
5.0–5.5), washed with loading buffer, loaded, and washed twice with
loading buffer. Fractions were eluted with a series of 1 ml 50 mM
sodium acetate, 500 mMNaCl elutions at progressively lower pHs (one
time pH 6.0, two times pH 5.0, three times pH 4.0). Elutions were
immediately supplemented with 0.05 ml of 1 M Tris pH 9.0 and snap
frozen on dry ice powder. Fractions enriched in CANC proteins, as
determined by analysis of SDS-PAGE-separated samples, were diluted
ﬁve to ten timeswith loading buffer and rerun. The ﬁnal eluted fractions
were then dialyzed against cold 20 mM Tris pH 8.0, 5 mM B-Me, 1 μM
ZnCl2 and frozen at −80 °C. Protein identities and purities were
assessed as for CA proteins.
In vitro RNA transcription
The nucleic acids used in the in vitro CANC assembly reactions
were prepared by T7 RNA polymerase transcription (Alfadhli et al.,
2009) from SalI (nt 1–4001) or PvuII (nt 1–692) linearized SP64HIV1-
4005 plasmids (kindly provided by J.C. Paillart, CNRS-Université de
Strasbourg). Brieﬂy, the plasmid digestion products were subjected to
phenol/chloroform extraction, after which DNAs were precipitated
using 1/10 vol of 3 M sodium acetate pH7.6 and two volumes of ice
cold ethanol. DNA pellets were dried and resuspended in TE buffer
(10 mM Tris pH7.4, 0.1 mM EDTA). In vitro transcription reactions
were performed using 2 μl of the T7 polymerase (New England Biolabs
M0251S), 10 μl of the supplied 10× buffer, 20 μl of the rNTPs (2.5 mM
for each rNTP), 1 μl of RNAsin (Promega 27838911 40 U/μl) and 3 μg of
the linearized DNA in a ﬁnal volume of 100 μl. Mixtures were
incubated 1 h at 37 °C, and then 1 μl of the polymerase and 10 μl of
the rNTPs were added, and the reactions were incubated for an
additional hour at 37 °C. After this incubation step, 1 μl of RNAse-free
DNAse (Roche 04716728001) was added to each transcription
reaction, and the mixtures were incubated at 37 °C for 10 min prior
to the addition of 2 μl RNAsin and 98 μl of DEPC treated water to
achieve a ﬁnal volume of 200 μl. RNAs were puriﬁed via twosuccessive phenol/chloroform extractions, and aqueous phases were
precipitated by the addition 50 μl of 4 M ammonium acetate and
700 μl ice-cold ethanol. Pelleted precipitates were washed twice with
70% ethanol, suspended in 200 μl DEPC-treated water, and reprecipi-
tated overnight at −80 °C after the addition of 20 μl of 3 M sodium
acetate, pH 7.6 and 700 μl ethanol. Final RNA pellets were washed
with 200 μl of 70% ethanol, vacuum dried, suspended in 20–30 μl of
DEPC-treated water, and stored at−80 °C. RNAs were analyzed by gel
electrophoresis. To do so, 2 μl samples and RNA size standards
(0.5–10 kb RNA ladder; Invitrogen 15623-200) were mixed with 8 μl
of loading buffer (25 mM MOPS, pH 7.0; 6.25 mM sodium acetate,
1.25 mMEDTA, 7.4% formaldehyde, 56.25% formamide, 6.25% glycerol,
0.01% bromophenol blue), heated for 10 min at 70 °C and then run on
a 6.67% formaldehyde gel (1–1.5% w/v agarose) using 1× running
buffer (20 mM MOPS pH7.0, 5 mM sodium acetate, 1 mM EDTA) in
both the gel and electrophoresis apparatus. Samples were electro-
phoresed 5 h at 100 V, at 4 °C. Following electrophoresis, gels were
washed 30 min in 20× SSC (3 M NaCl, 0.3 M sodium citrate), after
which RNAs were transferred overnight to nylon membranes
(Hybond-N+; GE healthcare RPN303B) by capillary action using
10× SSC. RNAs then were crosslinked by UV treatment (two times
120,000 μJ; UV Stratalinker), after which membranes were stained for
15 min with Methylene blue (300 mM sodium acetate pH 5.2, 5 mM
EDTA and 0.03% methylene blue). Stained membranes were washed
repeatedly with water until RNA bands were visible. RNA sizes were
veriﬁed by comparison with standards, and concentrations were
calculated by both densitometric comparison with size standards and
260 nm light absorbance assuming an extinction coefﬁcient of 1 OD
unit per 40 μg RNA.
CA assembly turbidity assays
HIV-1 CA assembly incubations were performed essentially as
described previously (Li et al., 2000; Ganser-Pornillos et al., 2004;
Barklis et al., 2009). Turbidity assays were performed at 25 °C using a
multiwell plate reader (Molecular devices 190) operating at 350 nm
wavelength. Wells were seeded with 20 μl of 50 μM CA, and assembly
was initiated by addition of an equal volume of 4 M NaCl. Spectral
measurements were taken every 2 min for 20 min and then every
5 min thereafter. For graphing purposes, optical density (OD) values
were normalized to those of WT samples performed in parallel.
Relative assembly rates (ΔOD/min) were estimated from initial slopes
(2 min) of the plots of absorbance versus time. Maximum values were
the highest ones obtained during 60 min incubations. All assays were
performed at least three independent times, and average values plus
standard deviations have been presented.
Fluorescence microscopy
Fluorescence microscopy (FM) assays of CA assembly were
performed as described previously (Barklis et al., 2009). Typically,
10 μl reactions included 80 μM protein and 1× FM assembly buffer
(50 mM Tris pH 7.0, 1 M NaCl and 5 mM B-Me), and were incubated
48 h at 4 °C. Samples so prepared were processed as described
(Barklis et al., 2009), using the following primary antibodies: for CA,
media supernatants of cells producing the mouse anti-CA monoclonal
antibody Hy183 (kindly provided by Bruce Chesebro, RockyMountain
Laboratory) were used without dilution; for Flag-tagged proteins, the
monoclonal Anti-Flag M2 FITC conjugate (Sigma, F-4049) was used at
a dilution of 1:2000; and for Myc-tagged proteins, the Anti-Myc
(clone 9E10) Alexa Fluor 555 conjugate (Millipore, 16–263) was used
at a dilution of 1:2000. Secondary antibodies used in conjunction with
Hy183 were AlexaFluor488- or AlexaFluor544-conjugated goat anti-
mouse IgG(H+L) antibodies (Invitrogen), used at dilutions of 1:500
to 1:2000. For assays in which Δ87–97 proteins were Flag-tagged and
I15D proteins were Myc-tagged, samples ﬁrst were subjected to a
145C.S. López et al. / Virology 417 (2011) 137–146complete round of antibody binding and wash steps with one of the
antibodies (anti-FlagM2 FITC conjugate) and thenwere subjected to a
second round of labeling using the anti-Myc (clone 9E10) Alexa
Fluor555 conjugate. After all antibody binding and wash steps,
samples were mounted using Fluoromount-G (SouthernBiotech
0100–01), sealed, and stored at 4 °C prior to viewing. FM imaging
was performed on a Zeiss AxioObserver ﬂuorescence microscopes
using 20× (LDA-Plan) and 63× (Planapochromat) objectives and a
Zeiss ﬁlter set 10 (excitation bandpass, 450–490; beamsplitter Fourier
transform, 510; emission bandpass, 515–565) for green ﬂuorophores
or Zeiss ﬁlter set 20 (excitation bandpass, 546/12; beamsplitter
Fourier transform, 560; emission bandpass, 575–640) for red
ﬂuorophores. Images were collected in gray-scale TIF format using
Zeiss Axiovision software. For mixing experiments, we did not
observe obvious differences between images of Flag-tagged Δ87–97
proteins and Myc-Tagged I15D proteins, so only images of the Flag-
tagged proteins are provided.
Quantitation of FM assembly assay results followed procedures
described previously (Barklis et al., 2009). Brieﬂy, gray scale TIF images
were opened in Image J, and featureswere highlighted using the Feature
J/FJ Laplacian command with a smoothing step of 1.0. Resulting
Laplacian images were thresholded manually using the Image/Adjust/
Threshold command, applying threshold values of approximately two
standard deviations below the Laplacian image brightness mean.
Thresholded images were converted into binary black-white images
with the Process/Binary/Make Binary Image J command, which
generated images in which tubes appeared as black lines against a
white background. For tube coverage tabulation, the Analyze/Analyze
Particles commandwas used,with the size parameter set at 0 to inﬁnity,
the circularityparameter set at 0.00 to 1.00, and selecting for theget area
fraction output setting, which yields the percentage of the total image
area covered by tubes. For each CA variant area fractions were obtained
from at least four images, along with images from WT incubations
performed in parallel. Results are depicted as areas covered by tubes
normalized to the results with WT incubations.
Electron microscopy
Typical assembly incubations for EM analysis employed the
conditions indicated above for FM incubations. After the incubations,
samples were lifted onto 400-mesh carbon-formvar grids (Ted Pella
01822-F) or 400-mesh ultrathin carbon-over-holey carbon grids (Ted
Pella 01824). Sampleswere lifted onto grids for 3 min,washed for 1 min
in water, wicked on ﬁlter paper, stained for 45 s in ﬁltered 1.33% uranyl
acetate,wicked, and air-dried for 5 min. Sampleswere viewed at 100 kV
on a Philips CM120 TEM, and images were collected as 1024×1024
pixel, 14-bit gray-scale Gatan Digital Micrograph 3 (DM3) ﬁles on a
Gatan794CCDmultiscan camera and converted into 8-bit gray-scale TIF
images using the program Digital Micrograph 3.4.0.
For quantitation of EM results, at least six 4.136 μm×4.136 μm gray
scale TIF images for each variantwere analyzed. Todo so, image features
were highlighted using the Feature J/FJ Laplacian command with a
smoothing step of 10 and the zero crossings parameter unselected.
Laplacian imageswere thresholded to low values of 0.10 andmaximum
high values. For tube coverage tabulation, the Analyze/Analyze Particles
command was used with the Analyze/Set Measurements area and
Feret's diameter options highlighted. The Analyze Particles command
was called with size and circularity arguments as for FM analysis, and
results (including particle ID numbers, particle areas, and Feret
diameters) were saved in table format. Tube candidates then were
excluded if they did not meet the criteria of having a Feret's diameter of
at least 50, and a (Feret)2/(area) value of at least 4. After performing
thesequaliﬁcation steps, total areas coveredby tubeswere summed and
divided by total areas to obtain area fractions covered by tubes. Results
are depicted as areas covered by tubes normalized to the results with
WT incubations.CANC assembly incubations
CANC assembly incubations were performed in the presence or
absence of RNA and/or CA proteins as indicated in the ﬁgure legends.
For standard reactions, 3 or 30 μMWT or Δ87–97 CANC proteins were
incubated in 10 or 20 μl reactions with HIV 1–4001 or 1–692 in vitro
transcribed RNAs (30 μM total nt concentration) at 4 °C for 24 h in
20 mMTris pH 7.0, 5 mMB-Me, 1 μMZnCl2. In reactions containing CA
proteins, the CANC and RNA components were pre-incubated 30 min
at 4 °C prior to addition of WT or Δ87–97 CA. Incomplete reactions in
which individual CANC, CA, or RNA components were excluded, also
were performed. For analysis, incubation products were processed for
EM as described above.
Immunogold incubations
The CANC samples processed for immunogold incubations were
assembled asmentioned above. For this assaywe utilized nickel grids
(Ted Pella 01800N-F) treated with poly-L-lysine (0.01% solution,
Sigma P4707) for 2 min at room temperature. Samples were lifted
onto these grids for 3 min, wicked on ﬁlter paper and incubated for
30 min at 4 °C in 4% (w/v) paraformaldehyde, 2.5% glutaraldehyde
(v/v) prepared in 1× phosphate saline buffer pH 7.4 (PBS). After this
step, the grids were wicked and washed in 1× PBS for 1 min. Grids
were blocked then in 1× PBS containing 0.5% BSA (PBS+BSA) for
30 min at room temperature, then incubated with the primary
antibody raised against the cyclophilin loop (Advanced Biotechnol-
ogies Inc., 13-102-100) at 1/500 dilution in PBS+BSA for another
30 min. The grids were then wicked, washed three times for 1 min in
PBS+BSA, wicked again and incubated for 30 min at roomtemperature
in 10 nm gold conjugated Goat anti mouse IgG (H+L) (AH) (Ted
Pella, 15751) 1/10 dilution in PBS+BSA. After this incubation step
the grids were washed three times for 1 min in PBS+BSA, followed
by a single wash in ﬁltered water. The grids were wicked on ﬁlter
paper and stained for 45 s in ﬁltered 1.33% uranyl acetate, wicked, and
air-dried for 5 min.
For analysis of immunogold samples, tubes were viewed and tube
lengths were measured on Image J. Gold particles along the length of
each tubewere counted andmeasured. For comparison of tube labeling,
total particle counts per unit length were tabulated. For comparison of
the locations of gold particles along tube lengths, one end of each tube
wasdeﬁned as its zero end, and corresponded to the onewithmore gold
particle labeling in the terminal 10% of the tube. Once zero ends were
assigned, distances of each gold particle from zero ends were tabulated.
To compile results for multiple tubes in each data set, distances of gold
particles from zero ends were converted from absolute distances to
normalized percentage distances, inwhich the absolute distance of each
particle from its zero endwas divided by the length of the tube. For each
data set, the numbers of particles along tube length intervals were
summed to generate histograms of gold particle counts versus
normalized distances from tube zero ends.
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